EP Patent

EP2225255A4 — Crystal forms of 2-[2-(4-chlorophenyl)ethoxy]adenosine

Assigned to King Pharmaceuticals Research and Development Inc · Expires 2011-07-20 · 15y expired

What this patent protects

Patent listed against regadenoson.

Drugs covered by this patent

Patent Metadata

Patent number
EP2225255A4
Jurisdiction
EP
Classification
—
Expires
2011-07-20
Drug substance claim
No
Drug product claim
No
Assignee
King Pharmaceuticals Research and Development Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.